
Ericsson said on Tuesday the closing of its $6.2 billion Vonage acquisition was delayed to the end of July, from the first half of the year, due to a pending investigation by a US national security panel.
The Swedish telecom equipment maker agreed to buy cloud communications firm Vonage in all-cash deal in November, as part of its efforts to broaden its 5G portfolio.
But, since then, Ericsson has faced a bribing scandal in Iraq that has led to the US Department of Justice and the Securities and Exchange Commission (SEC) opening investigations against the company.
Several analysts had estimated that the probes could either delay getting approval for the deal from US regulators or even derail it.
The deal is currently under review by the Committee on Foreign Investment in the United States (CFIUS), an interagency panel that reviews foreign investments for potential national security risks.
“Given that the committee’s review is ongoing, we cannot comment on any specifics,” an Ericsson spokesperson said.
Ericsson also said both the companies were working closely with CFIUS and the deal has cleared all other requisite foreign and US regulatory approval requirements. The deal is one of the largest in Ericsson’s history.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas